Back to Browse Journals » Substance Abuse and Rehabilitation » Volume 3 » Supplement 1

Meeting the substance abuse treatment needs of lesbian, bisexual and transgender women: implications from research to practice

Authors Stevens S

Received 22 September 2011

Accepted for publication 5 November 2011

Published 1 February 2012 Volume 2012:3(Supplement 1) Pages 27—36


Review by Single-blind

Peer reviewer comments 4

Sally Stevens

Southwest Institute for Research on Women (SIROW) and Department of Gender and Women’s Studies (GWS), University of Arizona, Tucson, AZ, USA

Abstract: Research on the incidence, etiology and substance abuse treatment needs of lesbian, bisexual and transgender (LBT) women is limited. Most research indicates higher levels of alcohol and drug abuse among these populations compared to their heterosexual counterparts, with recent research indicating that substance abuse is a particular concern for transgender individuals and an increasing problem among younger LBT individuals. Risk factors and reasons for substance abuse among sexual minority women are similar to those of heterosexual women, yet are substantially complicated by issues of family rejection and lack of social support, stigma and minority stress, as well as abuse and harassment. Historically, substance abuse prevention, early intervention, and clinical treatment programs were designed to meet the needs of the sexual majority population with relatively few programs designed to incorporate the specific needs of sexual minorities. This article reviews findings from previous studies and utilizes new data collected from community-based and residential substance abuse treatment programs to (1) examine issues relevant to LBT women and substance use, and (2) make recommendations for tailoring substance abuse treatment programs to meet the needs of these populations.

Keywords: lesbian, bisexual, transgender, substance abuse, family rejection, social support, stigma, minority stress, abuse, harassment

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Challenging nanoparticles: a target of personalized adhesion prevention strategy

Mynbaev OA, Eliseeva MY, Malvasi A, Tinelli A

International Journal of Nanomedicine 2014, 9:3375-3376

Published Date: 15 July 2014

Nanotechnology-based drug delivery systems and herbal medicines: a review

Bonifácio BV, Silva PB, Ramos MAS, Negri KMS, Bauab TM, Chorilli M

International Journal of Nanomedicine 2014, 9:1-15

Published Date: 9 December 2013

Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3

Gaikwad S, Ingle A, Gade A, Rai M, Falanga A, Incoronato N, Russo L, Galdiero S, Galdiero M

International Journal of Nanomedicine 2013, 8:4303-4314

Published Date: 6 November 2013

Pluronic mixed micelles overcoming methotrexate multidrug resistance: in vitro and in vivo evaluation

Chen Y, Sha X, Zhang W, Zhong W, Fan Z, Ren Q, Chen L, Fang X

International Journal of Nanomedicine 2013, 8:1463-1476

Published Date: 16 April 2013

Green synthesis of copper oxide nanoparticles using gum karaya as a biotemplate and their antibacterial application

Thekkae Padil VV, Černík M

International Journal of Nanomedicine 2013, 8:889-898

Published Date: 28 February 2013

The neuro-ophthalmology of HIV-AIDS review of Neurobehavioral HIV Medicine

Sudhakar P, Kedar S, Berger JR

Neurobehavioral HIV Medicine 2012, 4:99-111

Published Date: 18 September 2012

Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption

Zeng N, Gao X, Hu Q, Song Q, Xia H, Liu Z, Gu G, Jiang M, Pang Z, Chen H, Chen J, Fang L

International Journal of Nanomedicine 2012, 7:3703-3718

Published Date: 13 July 2012

Immune activation and neuropsychiatric symptoms in human immunodeficiency virus type 1 infection

Schroecksnadel S, Kurz K, Weiss G, Fuchs D

Neurobehavioral HIV Medicine 2012, 4:1-13

Published Date: 16 January 2012

Case of endogenous endophthalmitis caused by Streptococcus equisimilis

Shinsuke Suemori, Akira Sawada, Shinya Komori, et al

Clinical Ophthalmology 2010, 4:917-918

Published Date: 12 August 2010